This article is more than 5 years old. Information may no longer be current.

Upcoming NLA meeting offers insights on lipid management

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Cardiology Today will be onsite at National Lipid Association Scientific Session covering presentations on the hottest topics in lipidology.

The 4-day conference, starting Thursday, May 18, will feature intensive sessions on major topics in lipid research and the future of health care, as well as more interactive poster sessions in which attendees can speak directly to the researchers.

Past, present and future

According to the NLA website, the opening session will include an in-depth expert discussion and town hall where a panel of doctors discuss new insights on of lipid-lowering therapeutic agents.

Discussion will include how past knowledge of statins and other LDL-lowering therapies help inform the newest classes of specialized high-intensity therapies.

Updating new therapies

On Friday, May 19^th, there will be an interactive sessions featuring Samuel S. Gidding, MD, FNLA, chief of pediatric cardiology at Nemours/Alfred I. duPont Hospital for Children, Gerald F. Watts, DSc, PhD, DM, FRACP, FRCP, from Cardiometabolic Research Centre and Clinical Services of Royal Perth Hospital School of Medicine and Pharmacology at the University of Western Australia and Kees Hovingh, MD, PhD, MBA, from the University of Amsterdam, who will discuss recent developments and therapies for patients with familial hypercholesterolemia.

Christie M. Ballantyne

PCSK9 inhibitors

On Saturday, May 20^th, Christie M. Ballantyne, MD, FNLA, from Baylor College of Medicine, and colleagues will examine results of studies on the efficacy of PCSK9 inhibitors for prevention of CV events, as well as design of ongoing outcome trials.

According to the NLA, these data will be essential for providers and patients when discussing potential benefits, side effects and costs of nonstatin therapy.

The NLA will also unveil its updated recommendations for PCSK9 inhibitors.

For more information:

Healio.com will be reporting onsite from Philadelphia throughout the meeting. Visit Healio.com/Cardiology for breaking news, expert video perspectives and other updates.